Poolbeg Pharma's £4m raise shows ambition

  • Raising fresh capital is a familiar rhythm for early-stage biotech companies. For Poolbeg Pharma PLC (AIMOLB), the question is not simply whether it can fund its ambitions, but whether its pipeline can justify them.